New Treatment Options for Pulmonary Arterial Hypertension — The First Selective IP-receptor Agonist Selexipag
Cardiovascular Therapy and Prevention (Russian Federation) - Russian Federation
doi 10.15829/1728-8800-2019-6-80-87
Full Text
Open PDFAbstract
Available in full text
Date
December 22, 2019
Authors
Publisher
Silicea - Poligraf, LLC